ClinicalTrials.gg
RecruitingNCT06376149M3-JIAUpdated Oct 9, 2026

M3-JIA: Making Mindfulness Matter for Children With JIA

An interventional study of M3 Intervention group and M3 Waitlist Group in Juvenile Idiopathic Arthritis, Children and Mental Health, sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Recruiting at 3 sites in Canada. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Arthritis, Juvenile with a site in Canada — 13 open to participants now, 15 under way, 2 of them phase 3. Arthritis, Juvenile · Canada.

Planned enrollment
24th of 47
74 · median 74
Started
2024
with 1 other
No phase
20 of 53
6 open now
Primary completion
2027-07
later than 7 of 14 live
Registered
48th of 53
by date

Among the 53 studies in Arthritis, Juvenile with a site in Canada, this one is the 24th largest by planned enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2024, is one of 20 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 48th registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

13 of the 53 studies in Arthritis, Juvenile with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Arthritis, Juvenile with a site in Canada, or all of them as a file.
02

Study summary

The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric chronic disease. The child program is designed for children 4-12 years of age, with each lesson including a variety of concrete ways to teach children skills based on their age/developmental level.

Read the detailed description

This pilot RCT is essential to refine the implementation of the intervention to families with a child with JIA and collect information pertaining to the feasibility and effectiveness of the intervention in preparation for a subsequent multicentred trial across Canada. The investigator will propose to test if the M3© program improves the child's health related quality of life (HRQOL) and mental health for Children with JIA and caregivers. Additionally, to address the knowledge gap on the relationship between mental health and disease outcomes in JIA. M3 is a promising mindfulness-based intervention which may have mental health benefits for children with JIA and caregivers.

03

Conditions studied

  • Juvenile Idiopathic Arthritis
  • Children
  • Mental Health
  • Mental Well-being

Keywords

  • M3
  • mindfulness
04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 4 to 12 years diagnosed with JIA
  • Children have reasonable comprehension of spoken language and can follow simple instructions
  • Children with JIA and their caregivers are willing to attend intervention sessions and have access to technology and internet to attend the online sessions.
  • Children with JIA and their caregivers have an adequate understanding of English

Exclusion criteria

Exclusion Criteria:

  • Other major co-morbid disorders (e.g. Crohn's disease, diabetes, renal failure).
  • Concurrent enrollment in other intervention trials or practicing any complementary health interventions such as yoga, meditation, or daily mindfulness practice.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
74 participants (estimated)

Study arms

  • Other
    Experimental: Intervention Group

    Child-parent dyads will undergo a standardized 8-week course of Making Mindfulness Matter© (M3). The program will be delivered online using live, interactive sessions to groups of 4 to 8, for 1.5 hours each week for the parent group and 1 hour each week for the child group. Children and parents will attend separate on-line sessions and at the end of each child session, the parent will be asked to join their child on-line for a shared mindful exercise. Once 4 to 8 dyads are assigned to the intervention group, participants will be given the baseline questionnaires and start the intervention in the following week. Interventions: Behavioural: Making Mindfulness Matter© (M3)

    Behavioral: M3 Intervention group

  • Other
    Other: Waitlist Control

    Child-parent dyads randomized to the control arm will continue treatment as usual. Once 4 to 8 dyads are assigned to the control group, participants will be given the baseline questionnaires, They will complete Follow-up questionnaire and extended follow up questionnaires at comparable times to families in the intervention arm. With one extra set of questionnaires at the completion of the intervention. These dyads will be provided with the intervention at the next scheduled session; the goal is to provide the intervention to controls as soon as possible to avoid differential attrition between the intervention and control arm. During the intervention sessions, they will complete all feasibility surveys pertaining to the intervention and their satisfaction with each intervention session. Interventions: Behavioural: Making Mindfulness Matter© (M3)

    Behavioral: M3 Waitlist Group

Interventions

  • BehavioralM3 Intervention group

    The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.

  • BehavioralM3 Waitlist Group

    The M3© program offered online concurrently for parents and children (4-12 years of age). Each parent session is 90 minutes long, and each child session is 60 minutes long. Parents and children learn similar concepts, at developmentally appropriate levels.

06

What researchers measure

Primary outcomes

  1. conduct a pilot RCT to evaluate the effectiveness of a live-online mindfulness-based family intervention program, Making Mindfulness Matter (M3©) for children with JIA and their caregiver(s).

    At the start of each session, parents will complete a one-page (12-item) semi-structured questionnaire evaluating treatment fidelity, at home utilization of M3 skills. At the end of each session, parents will complete an overall feedback form on the intervention. Facilitators will complete a two-page questionnaire providing feedback on the session. At the start and end of the M3 program, children will be asked to complete a feeling face questionnaire rated on a 3-point scale about topics discussed in the group such as how our brain works when upset and what is mindfulness. The minimum score being 0 with the highest score being 10 where the higher the score means the better the outcome.

    Time frame: Throughout the study enrollment period and over the 8 weeks of intervention.

Secondary outcomes

  1. Effects of M3 on health related quality of life of children with JIA

    Peds Quality of life (PedsQL) is a 23-item measure for children ages 2-18 years that emphasizes a functional approach to quality of life by examining the child's sense of well-being and ability to engage in physical and social activities, to concentrate, think and remember, and to regulate behaviour. Generates an overall Peds-QL score, and four subscale scores: cognitive, emotional, social, and physical functioning. Parent report is obtained for children \<6 years old. The investigators will calculate the minimum clinically important difference (MCID). To calculate the MCID for the Peds-QL, the Patient Centred Global Ratings of Change will be used, a 5-item scale where respondents indicate the amount of change relative to baseline. Rating from -7 (much worse) through 0 (no change) to +7 (much better). This information will allow us to calculate the MCID for the Ped-QL, and thereby identify the proportion of patients who experience a clinically meaningful change following intervention.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  2. Effects of M3 on health quality of life for parents

    The Peds-QL Family Impact module is a 36-item measure designed to measure the impact of pediatric chronic health conditions on parents and the family. It measures parent self-reported physical, emotional, social, and cognitive functioning, communication, and worry, as well as parent-reported family daily activities and family relationships. Generates an overall score. Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better outcomes.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  3. Does M3 have a positive effect on children's severity of JIA

    The pediatric Symptom check list is a 17-question screening tool that is used to improve the recognition and treatment of psycho social problems in children ages 4 to 17 years as a parent reported measure. The total score is calculated by adding together the score for each of the 17 items. A score of 15 and over is considered at risk.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  4. Does M3 have a positive effect on children's executive function

    Behavioral Rating Inventory of Executive Function 2 (BRIEF) 63-item scale measuring parent-rated executive function and self-regulation in children. Generates a global executive composite, cognitive regulation index, emotion regulation index, behavior regulation index. Persons with T-score above 60 in a given scale are categorized as 'at-risk' for that domain.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

Other outcomes

  1. Does M3 have a positive effect on parents' stress

    Parenting Stress Index 4 - short form 36-item scale that helps identify sources of stress. Focused on three major domains of stress: child characteristics, parent characteristics, and situational/demographic factors. A summary and 3 subscale (Parental Distress, Parent-Child Dysfunctional Interaction and Difficult Child) scores are generated. Scores in the 81st percentile or higher are indicative of high stress.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  2. Does M3 have a positive effect on parents' depression and anxiety

    The PROMIS- short forms- depression, anxiety is an 8 question measures for parents personal physical, mental, and social well-being. Each item on the measure is rated on a 5-point scale with a range in score from 7 to 35 with higher scores indicating greater severity of depression and anxiety.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  3. Does M3 have a positive effect on Child's' depression and anxiety

    The Revised Child Anxiety and Depression scale- (RCADS) is a 47-item, youth self-report (ages 8-18 years) questionnaire with subscales including: separation anxiety disorder, social phobia, generalized anxiety disorder, panic disorder, obsessive compulsive disorder, and major depressive disorder. Parent report is obtained for children \<8 years old. Scores below 65 are in the clinically normal range. Scores between 66-69 are in the boardline clinical range and scores above 70 are in the clinical range.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  4. Does M3 have a positive effect on children's resiliency

    Child \&Youth Resiliency Measure (CYRM-R) is a 28 item resiliency self-report measure (ages 5-23 years). It looks at social ecological resiliency in children and adults. The possible range of scores for the total measure is 17 to 85, with higher scores indicating greater resilience.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

  5. Does M3 have a positive effect on parent resiliency

    Connor Davidson-resilience scale (CD-RISC) is a 25 item measure that looks at resilience or how well one is equipped to bounce back after stressful events, tragedy, or trauma. evaluated on a five-point Likert scale ranging from 0 to 4: these ratings result in a number between 0-100, and higher scores indicate higher resilience.

    Time frame: baseline, 9 weeks, 18 weeks and 2 months later.

07

Study locations

3 of 3 sites recruiting
  • McMaster Children's Hospital,
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
  • LHSC Children' Hosptial
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Sickids
    Toronto, Ontario M5G 1E8, Canada
    Recruiting
08

References and documents

Publications

  • Schonert-Reichl KA, Oberle E, Lawlor MS, Abbott D, Thomson K, Oberlander TF, Diamond A. Enhancing cognitive and social-emotional development through a simple-to-administer mindfulness-based school program for elementary school children: a randomized controlled trial. Dev Psychol. 2015 Jan;51(1):52-66. doi: 10.1037/a0038454. PubMed 25546595 ↗
  • Puka K, Bax K, Andrade A, Devries-Rizzo M, Gangam H, Levin S, Nouri MN, Prasad AN, Secco M, Zou G, Speechley KN. A live-online mindfulness-based intervention for children living with epilepsy and their families: protocol for a randomized controlled trial of Making Mindfulness Matter(c). Trials. 2020 Nov 11;21(1):922. doi: 10.1186/s13063-020-04792-3. PubMed 33176853 ↗
  • Treemarcki EB, Danguecan AN, Cunningham NR, Knight AM. Mental Health in Pediatric Rheumatology: An Opportunity to Improve Outcomes. Rheum Dis Clin North Am. 2022 Feb;48(1):67-90. doi: 10.1016/j.rdc.2021.09.012. PubMed 34798960 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2027, 34 months after the start.

Of 53 non-industry interventional studies with no phase under Arthritis, Juvenile, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's planned 34 months is above that.

Counting every sponsor, half of 56 studies reached it within 14 months; a quarter within 8 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Jul 2027 and completion Feb 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 19, 2024
StartActual
Sep 12, 2024
Primary completionEst.
Jul 2027was Dec 2025
CompletionEst.
Sep 2027was Feb 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Jul 2027
Oct 9, 2026
Study completion
Feb 2026→Sep 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Dec 2025→Jul 2027
    Study completion Feb 2026→Sep 2027
    + 4 other changes: verification date, oversight details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06376149
Collaborators
Brain Canada
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Sep 12, 2024
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Sarah Wells
Contact
sarah.wells@lhsc.on.ca
519-685-8500 ext. 56816
Roberta Berard, MD
Contact
roberta.berard@lhsc.on.ca
519-685-8266
Roberta Berard, MD
principal investigator · LHSC Children's Hospital/ Lawson Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion